Literature DB >> 23711451

Prognostic value of high sensitivity troponin T in patients with acutely decompensated heart failure and non-detectable conventional troponin T levels.

John T Parissis1, John Papadakis, Nikolaos P E Kadoglou, Christos Varounis, Panagiotis Psarogiannakopoulos, Penelope Rafouli-Stergiou, Ignatios Ikonomidis, Ioannis Paraskevaidis, Ioanna Dimopoulou, Aikaterini Zerva, Kleante Dima, Maria Anastasiou-Nana, Gerasimos Filippatos.   

Abstract

BACKGROUND: High-sensitivity troponin Τ (hs-TnΤ) allows the detection of very minor myocardial injury and has emerged as a novel prognostic marker in patients with cardiovascular disease. The aim of the present study was to determine the prognostic utility of hs-TnΤ levels in patients admitted to hospital for acutely decompensated heart failure (ADHF) and non-detectable conventional TnΤ levels.
METHODS: We prospectively enrolled 113 consecutive ADHF patients [77 (68%) men], mean age: 72.7±11.3 years, presented at admission with normal (<0.03 ng/ml) conventional (4th generation) TnΤ levels. Hs-TnΤ levels were measured by relevant commercially available kits and patients were monitored for major adverse events during a median follow-up period of 174 days (94-728 days).
RESULTS: In the univariate Cox proportional hazard analysis, hs-TnΤ was significantly related to death (HR=1.002 with 95%: confidence interval (CI) 1.001-1.003, P=0.001). In multivariate analysis, it remained a significant predictor of death after adjustment for age, gender, ejection fraction and creatinine levels (HR=1.003 with 95%: CI 1.001-1.005, P=0.008).
CONCLUSION: hs-TnΤ seems to identify high risk patients hospitalized for ADHF, independently of other classical prognostic biomarkers. Further studies are necessary to confirm the utility of this novel biomarker in risk stratification and management of patients with ADHF.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Acute heart failure; Biomarkers; High sensitivity troponin; Mortality

Mesh:

Substances:

Year:  2013        PMID: 23711451     DOI: 10.1016/j.ijcard.2013.05.056

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  9 in total

1.  The usefulness of selected biomarkers in aortic regurgitation.

Authors:  Piotr Duchnowski; Tomasz Hryniewiecki; Mariusz Kuśmierczyk; Piotr Szymański
Journal:  Cardiol J       Date:  2018-09-20       Impact factor: 2.737

2.  Role of Cardiac Troponin Levels in Acute Heart Failure.

Authors:  Nicholas Wettersten; Alan Maisel
Journal:  Card Fail Rev       Date:  2015-10

Review 3.  Multidimensional Approach of Heart Failure Diagnosis and Prognostication Utilizing Cardiac Imaging with Biomarkers.

Authors:  In-Cheol Kim; Byung-Su Yoo
Journal:  Diagnostics (Basel)       Date:  2022-06-01

Review 4.  Biomarkers in Acute Heart Failure: Diagnosis, Prognosis, and Treatment.

Authors:  Nicholas Wettersten
Journal:  Int J Heart Fail       Date:  2021-02-15

5.  Postoperative high-sensitivity troponin T as a predictor of sudden cardiac arrest in patients undergoing cardiac surgery.

Authors:  Piotr Duchnowski; Tomasz Hryniewiecki; Mariusz Kuśmierczyk; Piotr Szymański
Journal:  Cardiol J       Date:  2019-01-31       Impact factor: 2.737

6.  The Utility of Circulating and Imaging Biomarkers Alone and in Combination in Heart Failure.

Authors:  Biyanka Jaltotage; Girish Dwivedi; Daryl Eng Lee Ooi; Gnanadevan Mahadavan
Journal:  Curr Cardiol Rev       Date:  2021

Review 7.  Donor Cardiac Troponin for Prognosis of Adverse Outcomes in Cardiac Transplantation Recipients: a Systematic Review and Meta-analysis.

Authors:  Zhengyang Liu; Luke A Perry; Jahan C Penny-Dimri; Michael Handscombe; Isabella Overmars; Mark Plummer; Reny Segal; Julian A Smith
Journal:  Transplant Direct       Date:  2021-12-13

Review 8.  Type 2 MI and Myocardial Injury in the Era of High-sensitivity Troponin.

Authors:  Rifly Rafiudeen; Peter Barlis; Harvey D White; William van Gaal
Journal:  Eur Cardiol       Date:  2022-02-17

9.  Left Ventricular Dysfunction and CXCR3 Ligands in Hypertension: From Animal Experiments to a Population-Based Pilot Study.

Authors:  Raffaele Altara; Yu-Mei Gu; Harry A J Struijker-Boudier; Lutgarde Thijs; Jan A Staessen; W Matthijs Blankesteijn
Journal:  PLoS One       Date:  2015-10-27       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.